Principal Investigator
Juan Carlos Ramos
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20230192
Clinical Trial Summary
A Multicenter, Open-label Feasibility and Randomized Phase II Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma with or without HIV
Phase
Phase I
Funding Agency/Sponsor
National Cooperative Group
Disease
Lymphoma
Contact Information
Phone Number
+1 (305) 2437261